House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Oncology

Early and locally advanced breast cancer: diagnosis and management

NICE · 2025 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

This NICE guidance spans diagnosis, local and systemic treatment, complication management and follow-up for early or locally advanced breast cancer. Recent changes include close-margin surgery decisions, triple-negative neoadjuvant chemotherapy, endocrine choices and lymphoedema care. Multidisciplinary assessment and the person’s preferences guide treatment, with receptor status and recurrence risk determining systemic options. This overview of principal pathways is not a complete chemotherapy or radiotherapy protocol.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Complete pretreatment assessment and support

  • Provide a named breast-care specialist or equivalent key worker throughout diagnosis, treatment and follow-up, with prompt access to psychological support. Include fertility-preservation advice and opportunities to participate in research. [1]
  • Before treatment of early or locally advanced invasive cancer, assess the axilla with ultrasound and sample abnormal nodes using ultrasound-guided needle biopsy. [1]
  • Do not routinely request preoperative breast MRI for biopsy-proven invasive cancer or DCIS. Offer it for invasive cancer when extent is unclear on standard assessment, breast density prevents accurate mammography, or tumour sizing is needed before breast conservation for invasive lobular cancer. [1]
  • For invasive breast cancer, test ER, PR and HER2 simultaneously at initial histological diagnosis and ensure results are available for multidisciplinary treatment planning. Offer BRCA1/2 testing to women under 50 with triple-negative disease, including those without a relevant family history. [1]

Tailor breast and axillary surgery

  • After breast-conserving surgery, offer further surgery when invasive cancer or DCIS reaches the radial margin. Consider further surgery for clear but close margins below 2 mm in DCIS alone or below 1 mm in invasive cancer with or without DCIS, discussing benefits, harms, preferences and other treatment options. [1]
  • For DCIS treated with breast-conserving surgery, do not routinely perform sentinel-node biopsy unless invasive disease risk is high, for example a palpable mass or extensive microcalcifications. Offer sentinel-node biopsy when mastectomy is planned for DCIS. [1]
  • Use sentinel-node biopsy rather than axillary clearance to stage invasive cancer when ultrasound shows no nodal involvement or ultrasound-guided biopsy is negative. Pathologically proven nodal metastases on preoperative needle biopsy warrant axillary clearance in this pathway. [1]
  • After primary surgery, isolated tumour cells or sentinel-node micrometastases do not require further axillary treatment. Macrometastases generally warrant further axillary treatment; after breast conservation with 1–2 macrometastatic nodes and planned whole-breast radiation plus systemic therapy, discuss omission and its risks, within trials where available. [1]
  • Discuss reconstruction after mastectomy, including immediate and delayed options for women whether locally available or not, while respecting a preference for no reconstruction. Planned radiotherapy alone does not exclude immediate reconstruction; comorbidities may do so. [1]

Base systemic therapy on subtype and recurrence risk

  • Document systemic-therapy recommendations at the multidisciplinary meeting and make decisions with the person using prognostic and predictive features, expected benefit and toxicity. Where adjuvant chemotherapy is indicated, NICE recommends a taxane-and-anthracycline regimen, accounting for relevant appraisal-specific treatment conditions. [1]
  • When neoadjuvant chemotherapy is indicated for triple-negative invasive cancer, offer a platinum, taxane and anthracycline regimen after discussing benefits and harms. Pembrolizumab with chemotherapy followed by adjuvant pembrolizumab alone is a NICE option for locally advanced disease or high-risk early disease, subject to its full appraisal. [1]
  • Olaparib is a NICE adjuvant option, alone or with endocrine therapy, for adults with germline BRCA1/2 mutations and high-risk HER2-negative early cancer after neoadjuvant or adjuvant chemotherapy. Apply the complete appraisal criteria. [1]
  • For HER2-positive invasive cancer, offer neoadjuvant chemotherapy when indicated. Residual invasive disease in breast or nodes after neoadjuvant taxane-based and HER2-targeted therapy is an indication for considering trastuzumab emtansine under its NICE appraisal. [1]
  • Offer adjuvant trastuzumab for HER2-positive T1c or larger invasive cancer, combined with other indicated modalities. For T1a/T1b disease, consider it individually using comorbidities, prognostic features, chemotherapy toxicity and preferences. [1]

Match endocrine treatment to ovarian or testicular function

  • Offer adjuvant endocrine therapy for ER-positive invasive cancer. For premenopausal or perimenopausal people with ovaries, discuss tamoxifen alone, ovarian suppression plus tamoxifen, or ovarian suppression plus an aromatase inhibitor; suppression may offer more benefit when recurrence risk is higher. [1]
  • After menopause, offer an aromatase inhibitor initially for medium- or high-risk ER-positive invasive disease. Offer tamoxifen for low recurrence risk or when an aromatase inhibitor is contraindicated or not tolerated. [1]
  • For people with testes and ER-positive invasive cancer, offer tamoxifen. If unsuitable or not tolerated, consider testicular suppression with an aromatase inhibitor; do not use an aromatase inhibitor alone. Discuss treatment-specific adverse effects. [1]

Select radiation by surgery and regional treatment needs

  • Offer whole-breast radiotherapy to women with invasive breast cancer after breast-conserving surgery with clear margins. For women with DCIS after breast-conserving surgery with clear margins, consider radiation through a shared benefit–risk discussion. [1]
  • After mastectomy, offer radiotherapy for node-positive macrometastatic disease or involved resection margins, and consider it for node-negative T3/T4 disease. Do not offer it to patients at low local-recurrence risk. [1]
  • For invasive cancer without regional-node irradiation, offer 26 Gy in 5 fractions over 1 week to the breast or chest wall. Consider 40 Gy in 15 fractions over 3 weeks for increased radiation sensitivity, implant reconstruction or other acceptability factors. With regional-node irradiation, offer 40 Gy in 15 fractions over 3 weeks. [1]

Address complications and arrange surveillance

  • For breast-cancer-related lymphoedema, refer promptly to a specialist service and assess treatable causes before management. Compression is first-stage treatment for established lymphoedema, but should not be offered solely for prevention. Reassure patients that physical activity does not worsen lymphoedema. [1]
  • Offer baseline bone-density assessment to women with invasive cancer who are not receiving adjuvant bisphosphonates and are starting an aromatase inhibitor or ovarian suppression/ablation, or have treatment-induced menopause. Do not request it solely for tamoxifen treatment. [1]
  • Offer annual mammography for 5 years after or during breast-cancer treatment, including DCIS; women continue annually until entry to the relevant UK screening programme. Do not image the mastectomy-side soft tissues with mammography, or routinely use ultrasound or MRI for surveillance. [1]
  • Provide a written follow-up plan naming the responsible clinicians, adjuvant-therapy review dates, mammography schedule, symptoms requiring advice and routes back to specialist care. Share it with the patient and primary care. [1]

Limitations and use

  • Detailed drug doses, cardiac monitoring, all targeted-drug appraisals, extended endocrine therapy and complete neoadjuvant pathways are not reproduced. Technology-appraisal options require their full eligibility and prescribing conditions; UK commissioning rules do not establish Indian access.
  • Selected radiation recommendations are summarized; criteria for partial-breast treatment, omission, boosts and individual regional-node fields require the complete guideline.
  • Genetic testing recommendations here are not a complete contemporary germline-testing policy, and surveillance intervals include UK screening-programme assumptions.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Early and locally advanced breast cancer: diagnosis and management

    Selected recommendation material consulted

Clinical guideline

Publication details

Issuing organisation
NICE
First published
18 July 2018
Publisher’s latest update
14 April 2025
Resource type
Clinical guideline · House clinical summary
Source setting
United Kingdom

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Complete pretreatment assessment and support
  • Tailor breast and axillary surgery
  • Base systemic therapy on subtype and recurrence risk
  • Match endocrine treatment to ovarian or testicular function
  • Select radiation by surgery and regional treatment needs
  • Address complications and arrange surveillance
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House